Literature DB >> 19995099

Sedative load among long-term care facility residents with and without dementia: a cross-sectional study.

J Simon Bell1, Heidi T Taipale, Helena Soini, Kaisu H Pitkälä.   

Abstract

BACKGROUND AND
OBJECTIVE: People with cognitive impairment are particularly susceptible to adverse drug events linked to sedative and psychotropic drugs. A model to calculate sedative load has been developed to quantify the cumulative effect of taking multiple drugs with sedative properties. The objective of this study was to describe the sedative load and use of sedative and psychotropic drugs among long-term care facility residents with and without dementia.
METHODS: Cross-sectional data were collected from all 53 long-term care wards in Helsinki, Finland, in September 2003. Of the 1444 eligible residents, consent to participate was obtained for 1087 (75%) residents. Medication and diagnostic data were available for 1052 residents. All drugs were classified using the Anatomical Therapeutic Chemical (ATC) classification system. Sedative load was calculated for each resident using a previously published four-group model.
RESULTS: Of the 1052 residents, 781 (74.2%) were determined to have dementia. Residents with and without dementia had a similar sedative load (mean 3.0 vs 2.7, p = 0.267), but residents with dementia were taking fewer drugs than residents without dementia (mean 6.7 vs 7.4, p = 0.011). Residents with dementia were more frequent users of antipsychotics (42.8% vs 32.8%, p = 0.004), but less frequent users of antidepressants (35.6% vs 46.1%, p = 0.002) and sedative-hypnotics (22.8% vs 27.7%, p = 0.003) than residents without dementia. The most frequently used primary sedatives among people with dementia were temazepam (n = 122, 15.6%), oxazepam (n = 98, 12.5%) and lorazepam (n = 95, 12.2%). The most frequently used drugs with sedation as a prominent adverse effect or preparations with a sedating component among people with dementia were citalopram (n = 183, 23.4%), risperidone (n = 155, 19.8%) and olanzapine (n = 73, 9.3%).
CONCLUSIONS: Residents with dementia were less frequent users of sedative-hypnotic drugs than residents without dementia. However, residents with and without dementia had a similar sedative load. Clinicians should be aware of the extent to which all individual drugs, not only those prescribed for intentional sedation, contribute to a resident's sedative load. The very high rates of sedative and psychotropic use observed in long-term care facility residents highlight the need for new strategies to optimize drug use.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19995099     DOI: 10.2165/11531460-000000000-00000

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  52 in total

1.  Psychotropic drugs in nursing- and old-age homes: relationships between needs of care and mental health status.

Authors:  Ing-Britt Holmquist; Bengt Svensson; Peter Höglund
Journal:  Eur J Clin Pharmacol       Date:  2003-09-27       Impact factor: 2.953

2.  Adverse drug events in cognitively impaired elderly patients.

Authors:  Hooman Ganjavi; Nathan Herrmann; Paula A Rochon; Papita Sharma; Monica Lee; Daniel Cassel; Morris Freedman; Sandra E Black; Krista L Lanctôt
Journal:  Dement Geriatr Cogn Disord       Date:  2007-03-29       Impact factor: 2.959

3.  To what extent does the indicator "concurrent use of three or more psychotropic drugs" capture use of potentially inappropriate psychotropics among the elderly?

Authors:  Eva Lesén; Max Petzold; Karolina Andersson; Anders Carlsten
Journal:  Eur J Clin Pharmacol       Date:  2009-02-12       Impact factor: 2.953

4.  Sedative load and mortality among residents of long-term care facilities: a prospective cohort study.

Authors:  Heidi T Taipale; J Simon Bell; Helena Soini; Kaisu H Pitkälä
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

5.  The management of depression in older nursing home residents.

Authors:  Mary N Brown; Kate L Lapane; Andrea F Luisi
Journal:  J Am Geriatr Soc       Date:  2002-01       Impact factor: 5.562

6.  Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.

Authors:  Lon S Schneider; Karen S Dagerman; Philip Insel
Journal:  JAMA       Date:  2005-10-19       Impact factor: 56.272

7.  The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial.

Authors:  Clive Ballard; Maria Luisa Hanney; Megan Theodoulou; Simon Douglas; Rupert McShane; Katja Kossakowski; Randeep Gill; Edmund Juszczak; Ly-Mee Yu; Robin Jacoby
Journal:  Lancet Neurol       Date:  2009-01-08       Impact factor: 44.182

8.  Gender, living arrangements, and social circumstances as determinants of entry into and exit from long-term institutional care at older ages: a 6-year follow-up study of older Finns.

Authors:  Pekka Martikainen; Heta Moustgaard; Michael Murphy; Elina K Einiö; Seppo Koskinen; Tuija Martelin; Anja Noro
Journal:  Gerontologist       Date:  2009-03-19

Review 9.  Clinical pharmacology in the geriatric patient.

Authors:  Sarah N Hilmer; Andrew J McLachlan; David G Le Couteur
Journal:  Fundam Clin Pharmacol       Date:  2007-06       Impact factor: 2.748

10.  Number and dosage of central nervous system medications on recurrent falls in community elders: the Health, Aging and Body Composition study.

Authors:  Joseph T Hanlon; Robert M Boudreau; Yazan F Roumani; Anne B Newman; Christine M Ruby; Rollin M Wright; Sarah N Hilmer; Ronald I Shorr; Douglas C Bauer; Eleanor M Simonsick; Stephanie A Studenski
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2009-02-04       Impact factor: 6.053

View more
  9 in total

Review 1.  Second-generation antipsychotics in dementia: beyond safety concerns. A clinical, systematic review of efficacy data from randomised controlled trials.

Authors:  Salvatore Gentile
Journal:  Psychopharmacology (Berl)       Date:  2010-07-27       Impact factor: 4.530

2.  Antipsychotic-induced somnolence in mothers with schizophrenia.

Authors:  Mary V Seeman
Journal:  Psychiatr Q       Date:  2012-03

Review 3.  Antipsychotic Use in Dementia.

Authors:  Julia Kirkham; Chelsea Sherman; Clive Velkers; Colleen Maxwell; Sudeep Gill; Paula Rochon; Dallas Seitz
Journal:  Can J Psychiatry       Date:  2016-10-08       Impact factor: 4.356

4.  Sedative load among community-dwelling people aged 75 years and older: a population-based study.

Authors:  Heidi T Taipale; J Simon Bell; Maija Uusi-Kokko; Eija Lönnroos; Raimo Sulkava; Sirpa Hartikainen
Journal:  Drugs Aging       Date:  2011-11-01       Impact factor: 3.923

5.  Concomitant use of SSRIs, NSAIDs/aspirin and gastroprotective drugs among residents of long-term care facilities: a medical record review.

Authors:  J Simon Bell; Heidi T Taipale; Helena Soini; Kaisu H Pitkälä
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

6.  Polypharmacy and medication regimen complexity as factors associated with staff informant rated quality of life in residents of aged care facilities: a cross-sectional study.

Authors:  Samanta Lalic; Kris M Jamsen; Barbara C Wimmer; Edwin C K Tan; Sarah N Hilmer; Leonie Robson; Tina Emery; J Simon Bell
Journal:  Eur J Clin Pharmacol       Date:  2016-06-02       Impact factor: 2.953

7.  Sedative load of medications prescribed for older people with dementia in care homes.

Authors:  Carole Parsons; Jane Haydock; Elspeth Mathie; Natasha Baron; Ina Machen; Elizabeth Stevenson; Sarah Amador; Claire Goodman
Journal:  BMC Geriatr       Date:  2011-09-30       Impact factor: 3.921

8.  Quantifying Anticholinergic Burden and Sedative Load in Older Adults with Polypharmacy: A Systematic Review of Risk Scales and Models.

Authors:  Sweilem B Al Rihani; Malavika Deodhar; Lucy I Darakjian; Pamela Dow; Matt K Smith; Ravil Bikmetov; Jacques Turgeon; Veronique Michaud
Journal:  Drugs Aging       Date:  2021-11-09       Impact factor: 3.923

Review 9.  Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions.

Authors:  Luis Agüera-Ortiz; Ganesh M Babulal; Marie-Andrée Bruneau; Byron Creese; Fabrizia D'Antonio; Corinne E Fischer; Jennifer R Gatchel; Zahinoor Ismail; Sanjeev Kumar; William J McGeown; Moyra E Mortby; Nicolas A Nuñez; Fabricio F de Oliveira; Arturo X Pereiro; Ramit Ravona-Springer; Hillary J Rouse; Huali Wang; Krista L Lanctôt
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.